{"id":"4ae171e5-0a14-551f-8956-095400ea9cda","stable_key":"d2e91bc7-8177-5ad3-ad9b-5d65813ce082:naringenin-cyp-weak-null","predicate":"weakly_or_not_inhibits","statement":"Naringenin sulfate and glucuronide conjugates showed no or only weak inhibition of CYP2C9, CYP2C19 and CYP3A4 in the tested assays.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"ebaa4627-096e-5172-88b6-8519577fa1eb","mechanism_event_label":"Naringenin sulfate and glucuronide conjugates showed no or only weak inhibition of CYP2C9, CYP2C19 and CYP3A4 in the tested assays.","subject":{"id":"8d3fb1b0-bcda-52f6-9999-0259e2e56630","slug":"naringenin-sulfate-pool","display_name":"Naringenin sulfate conjugates","entity_type_key":"small_molecule"},"object":{"id":"309d7280-de3b-5aea-95ee-37ccf55f71ca","slug":"human-cyp2c9-2c19-3a4-panel","display_name":"Human CYP2C9/CYP2C19/CYP3A4 assay panel","entity_type_key":"protein_set"},"evidence_count":1,"mechanism_event":{"id":"ebaa4627-096e-5172-88b6-8519577fa1eb","stable_key":"d2e91bc7-8177-5ad3-ad9b-5d65813ce082:naringenin-cyp-weak-null-event","event_type":"observed_relationship","label":"Naringenin sulfate and glucuronide conjugates showed no or only weak inhibition of CYP2C9, CYP2C19 and CYP3A4 in the tested assays.","description":"Naringenin sulfate and glucuronide conjugates showed no or only weak inhibition of CYP2C9, CYP2C19 and CYP3A4 in the tested assays.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"8d3fb1b0-bcda-52f6-9999-0259e2e56630","slug":"naringenin-sulfate-pool","display_name":"Naringenin sulfate conjugates","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"309d7280-de3b-5aea-95ee-37ccf55f71ca","slug":"human-cyp2c9-2c19-3a4-panel","display_name":"Human CYP2C9/CYP2C19/CYP3A4 assay panel","entity_type_key":"protein_set"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"d7acec3a-1dbb-5111-8767-2cd739c8939e","slug":"naringenin-glucuronide-pool","display_name":"Naringenin glucuronide conjugates","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Naringenin conjugate concentration series","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Acute enzyme incubation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human CYP enzyme assays","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"This is a useful negative/weak result for the tested enzymes, not a complete drug-interaction screen.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Naringenin chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"naringenin","display_name":"Naringenin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human CYP enzyme assays","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Naringenin sulfate and glucuronide conjugates showed no or only weak inhibition of CYP2C9, CYP2C19 and CYP3A4 in the tested assays.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters. (2023). https://pubmed.ncbi.nlm.nih.gov/36481402/ DOI: 10.1016/j.biopha.2022.114078","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vitro","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"CYP2C9, CYP2C19 and CYP3A4 activity","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"c2c6c2cf-50aa-581d-9ae5-ddfa27170f58","evidence_kind":"source_excerpt","locator":"Lines 77-86","start_line":77,"end_line":86,"excerpt":"## naringenin-cyp-weak-null\nNaringenin sulfate and glucuronide conjugates showed no or only weak inhibition of CYP2C9, CYP2C19 and CYP3A4 in the tested assays.\nModel/species: Human CYP enzyme assays\nTissue/system: CYP2C9, CYP2C19 and CYP3A4 activity\nExposure: Naringenin conjugate concentration series\nRoute: In vitro\nDuration: Acute enzyme incubation\nLimits: This is a useful negative/weak result for the tested enzymes, not a complete drug-interaction screen.\nPrimary reference: Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters. (2023). https://pubmed.ncbi.nlm.nih.gov/36481402/ DOI: 10.1016/j.biopha.2022.114078\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Human CYP enzyme assays","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2804932d-46eb-5c43-8a45-0505e6b1ee05","stable_key":"import-d2e91bc7-8177-5ad3-ad9b-5d65813ce082","title":"Naringenin: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"e74776bf312a9ab53a4510c483e36e3093829e8c38725b9ae061e59e86f1145a","revision_id":"b96b5487-2b33-56ff-8955-9e8c0833533b","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}